COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assesse...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the neurological sciences Vol. 434; p. 120155
Main Authors:	Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 15.03.2022
Subjects:	Acute relapse Adult Adverse events Antibodies, Viral BNT162 Vaccine COVID-19 COVID-19 - prevention & control COVID-19 Vaccines - adverse effects Humans Immune response Multiple sclerosis Multiple Sclerosis - drug therapy Neurology SARS-CoV-2 Third booster dose Vaccination Vaccination - adverse effects COVID-19 Third booster dose Multiple sclerosis Immune response Adverse events Vaccination Acute relapse
ISSN:	0022-510X, 1878-5883, 1878-5883
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!